| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 06/20/2002 | WO2002047702A1 Compositions for inducing secretion of insulin-like growth factor-1 |
| 06/20/2002 | WO2002047697A2 Fractions of snake blood, their preparation and use as therapeutic agents |
| 06/20/2002 | WO2002030888A3 Tricyclic compounds and uses thereof |
| 06/20/2002 | WO2002022571A3 Compounds and methods for inhibiting alpha-1 beta-1 integrins |
| 06/20/2002 | WO2001089570A3 Combination of growth hormone secretagogues and antidepressants |
| 06/20/2002 | WO2001085942A3 Cytoskeleton-associated proteins |
| 06/20/2002 | WO2001072830A3 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
| 06/20/2002 | WO2001044445A8 Human lyases and associated proteins |
| 06/20/2002 | WO2001003688A3 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
| 06/20/2002 | WO2000076451A3 Pharmaceutical composition comprising no or at least a no donor compound inducing no formation in cells |
| 06/20/2002 | WO2000052210A9 Methods for targeting rna molecules |
| 06/20/2002 | US20020077465 Nuceotide sequences coding enzymatic polypeptide for use in the treatment and prevention of inflammation, cancer, muuscle disorders and thrombosis |
| 06/20/2002 | US20020077461 Pharmaceutical formulation |
| 06/20/2002 | US20020077361 Can be administered with conventional drugs to treat psychiatric or central nervous disorders to improve their efficacy or reduce their side effects |
| 06/20/2002 | US20020077342 For use in therapy of epilepsy, depression, tension, gastrointestinal disorders, pain, inflammation |
| 06/20/2002 | US20020077337 Chemical compounds |
| 06/20/2002 | US20020077333 For therapy inflammation, inflammatory diseases, immunologic diseases and other diseases mediated by tumor necrosis factor-alpha (TNF-alpha) and/or interleukin 6 or 10 and/or enzyme cyclooxygenase-2 (COX-2) |
| 06/20/2002 | US20020077329 EP4 receptor inhibitors to treat rheumatoid arthritis |
| 06/20/2002 | US20020077324 Novel polyhydroxypyrazine derivatives, their preparation and the pharmaceutical compostions which comprise them |
| 06/20/2002 | US20020077321 For therapy of tumor metastasis, solid tumor growth (neoplasia), osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, osteopenia, angiogenesis, including tumor angiogenesis and lymphangiogenesis |
| 06/20/2002 | US20020077296 High-throughput screening method |
| 06/20/2002 | US20020076705 Nucleotide sequences which code preferential polypeptide; for use in the detection, treatment, and prevention of alzheimer's, parkinson's, huntington's, Tourette Syndrome, meningitis, encephalitis, congenital disorders and brain |
| 06/20/2002 | US20020076399 Treatment of immune diseases |
| 06/20/2002 | CA2431406A1 Quinazolinone derivatives |
| 06/20/2002 | CA2428216A1 Secreted proteins |
| 06/19/2002 | EP1214443A1 Telomere restoration and extension of cell life-span in animals cloned from senescent somatic cells |
| 06/19/2002 | EP1214440A2 Sequence-specific dna recombination in eukaryotic cells |
| 06/19/2002 | EP1214422A1 Phosphatases which activate map kinase pathways |
| 06/19/2002 | EP1214404A1 Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
| 06/19/2002 | EP1214350A1 Peptides for combating the autoantibodies that are responsible for dilatative cardiomyopathy (dcm) |
| 06/19/2002 | EP1214342A1 Steroid hormone receptor polynucleotides, polypeptides, and antibodies |
| 06/19/2002 | EP1214337A2 Proteins associated with cell differentiation |
| 06/19/2002 | EP1214318A1 Imidazo[1,2-a]pyridine and pyrazolo[2,3-a]pyridine derivatives |
| 06/19/2002 | EP1214303A1 Heterocyclic compounds and methods of use thereof |
| 06/19/2002 | EP1214089A1 Therapeutic uses of m3 polypeptide |
| 06/19/2002 | EP1214075A1 POLYMORPHS OF N-METHYL-N-(3- 3- 2-THIENYLCARBONYL]-PYRAZOL- 1,5-$g(a)]-PYRIMIDIN-7-YL PHENYL)ACETAMIDE AND COMPOSITIONS AND METHODS RELATED THERETO |
| 06/19/2002 | CN1354745A Ethanesulfonyl-piperidine derivatives |
| 06/19/2002 | CN1354670A Therapeutic agent comprising botulinum neurotoxin |
| 06/19/2002 | CN1354653A Compressed compositions comprising clarified xanthan gum |
| 06/19/2002 | CN1354640A Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents |
| 06/18/2002 | US6407094 Glutamate receptor antagonists |
| 06/13/2002 | WO2002046749A2 Screening method for identifying compounds that selectively induce interferon alpha |
| 06/13/2002 | WO2002046409A2 Proteins and nucleic acids encoding same |
| 06/13/2002 | WO2002046384A2 Kinases and phosphatases sequences, and use thereof |
| 06/13/2002 | WO2002046383A2 Protein modification and maintenance molecules |
| 06/13/2002 | WO2002046373A1 Method of collecting placental stem cells |
| 06/13/2002 | WO2002046225A2 Use of sarp-1 for the treatment and/or prevention of scleroderma |
| 06/13/2002 | WO2002046184A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 06/13/2002 | WO2002046178A2 Benzofuran and benzothiophene derivatives as selective cox-2 inhibitors |
| 06/13/2002 | WO2002046167A1 Benzyl (idene)-lactams and their use as 5ht1-receptor ligands |
| 06/13/2002 | WO2002046166A1 Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists |
| 06/13/2002 | WO2002046147A2 Perturbed membrane-binding compounds |
| 06/13/2002 | WO2002045749A2 Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4 |
| 06/13/2002 | WO2002045711A1 Use of anti-muscarinic agents and calcium channel blockers in combination |
| 06/13/2002 | WO2002019967A3 Substituted hydrazine derivatives |
| 06/13/2002 | WO2002012244A3 Polymorphs of zaleplon and methods for the preparation thereof |
| 06/13/2002 | WO2001094415A3 Nuclear hormone receptor |
| 06/13/2002 | WO2001079170A3 Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof |
| 06/13/2002 | WO2001074839A3 Methods of making the 4-n-butylcyclohexanoic and the undecanoic acid esters of (7 alpha, 11 beta)-dimethyl-17 beta-hydroxy-4-estren-3-one and their medical use |
| 06/13/2002 | WO2001059103A3 Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression |
| 06/13/2002 | WO2001010444A3 A method of effecting phosphorylation in eucaryotic cells using thiamine triphosphate |
| 06/13/2002 | US20020072798 Muscle tissue engineering |
| 06/13/2002 | US20020072631 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 06/13/2002 | US20020072630 Therapy |
| 06/13/2002 | US20020072527 Polymorphs of zaleplon and methods for the preparation thereof |
| 06/13/2002 | US20020072517 Substituted cyclic amine metalloprotease inhibitors |
| 06/13/2002 | US20020071843 Targeted therapeutic agents |
| 06/13/2002 | CA2678490A1 Isolated placental perfusate and placental cells isolated therefrom |
| 06/13/2002 | CA2437048A1 Benzofuran and benzothiophene derivatives as selective cox-2 inhibitors |
| 06/13/2002 | CA2436732A1 Protein modification and maintenance molecules |
| 06/13/2002 | CA2436601A1 Perturbed membrane-binding compounds |
| 06/13/2002 | CA2435467A1 Benzyl (idene)-lactams and their use as 5ht1-receptor ligands |
| 06/13/2002 | CA2430989A1 Method of collecting placental stem cells |
| 06/13/2002 | CA2430558A1 Proteins and nucleic acids encoding same |
| 06/13/2002 | CA2430206A1 Screening method for identifying compounds that selectively induce interferon alpha |
| 06/13/2002 | CA2429641A1 Kinases and phosphatases |
| 06/13/2002 | CA2428092A1 Use of sarp-1 for the treatment and/or prevention of scleroderma |
| 06/13/2002 | CA2427430A1 Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4 |
| 06/12/2002 | EP1212941A2 Modulating ramp activity |
| 06/12/2002 | EP1212433A2 Protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 06/12/2002 | EP1212404A2 Isolation of muscle-derived stem cells and uses therefore |
| 06/12/2002 | EP1212355A2 Pharmaceutical compositions and methods of using secreted frizzled related protein |
| 06/12/2002 | EP1212353A1 Small cyclic mimics of brain-derived neurotrophic factor (bdnf) |
| 06/12/2002 | EP1212344A1 B7-like polynucleotides, polypeptides, and antibodies |
| 06/12/2002 | EP1212328A1 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 06/12/2002 | EP1212319A2 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
| 06/12/2002 | EP1212302A1 Compounds and pharmaceutical compositions as cathepsin s inhibitors |
| 06/12/2002 | EP1212052A2 Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate |
| 06/12/2002 | CN1353704A 取代吡唑化合物 A substituted pyrazole compound |
| 06/12/2002 | CN1353699A Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |
| 06/12/2002 | CN1353690A Bradykinin receptor antagonists |
| 06/12/2002 | CN1353605A Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and use thereof |
| 06/12/2002 | CN1352943A Medicine for treating disease of motor neuron |
| 06/11/2002 | US6403830 Amidino compound and salts thereof useful as nitric oxide synthase inhibitors |
| 06/11/2002 | US6403574 Tranquilizers, antiepileptic, muscle relaxation prior to surgery |
| 06/11/2002 | US6403561 Disorders associated with the inactivation or excessive degradation of cholecystokinin; inhibiting the enzymatic hydrolysis of cholecystokinin 1-(2(s)-aminobutyryl)-2(s)-indolinecarboxylic acid |
| 06/11/2002 | US6403349 Elongation of polyunsaturated fatty acid such as linolenic acid to dihomogamma linolenic acid; nucleotide sequence encodes polypeptide; genetic engineering; animal feeds, nutrients, cosmetics |
| 06/11/2002 | US6403091 Produced by the hybridoma having atcc accession no. hb 10916. |
| 06/11/2002 | US6403087 Soluble lymphotoxin-β receptors as therapeutic agents for the treatment of immunological disease |
| 06/11/2002 | CA2239705C Quinazoline-4-one ampa antagonists |